✦ LIBER ✦

Chronic Kidney Disease and Cardiovascular Therapeutics: Time to Close the Evidence Gaps

✍ Scribed by Tara I. Chang; Glenn M. Chertow

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Aspirin and the Prevention of Cardiovasc

✍ Ravinder K. Wali 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 135 KB

Achievement of Therapeutic Goals and Uti

✍ Carlos Lahoz; Jose M. Mostaza; María Teresa Mantilla; Manuel Taboada; Salvador T 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 96 KB

PO13-348 EVIDENCE-BASED CARDIOVASCULAR T

✍ Lahoz, C.; Mantilla, M.T.; Taboada, M.; Soler, B.; Martín-Jadraque, L.; Tranche, 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 95 KB

CLOSING THE THERAPEUTIC GAP IN HIGH RISK

✍ Akosah, Kwame O.; DeGuzman, Pamela; Goldberg, Randal; Beller, George A. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 240 KB

The AGE–RAGE Pathway and Its Relation to

✍ Leurs, Paul; Lindholm, Bengt 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 157 KB

The epidemiology of chronic kidney disea

✍ Vandana Menon; Mark J. Sarnak 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 142 KB